Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck

“Respiratory Syncytial Virus Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Respiratory Syncytial Virus Market.

The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Respiratory Syncytial Virus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Respiratory Syncytial Virus treatment therapies with a considerable amount of success over the years. 

• Respiratory Syncytial Virus companies working in the treatment market are GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others, are developing therapies for the Respiratory Syncytial Virus treatment 

• Emerging Respiratory Syncytial Virus therapies in the different phases of clinical trials are- Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others are expected to have a significant impact on the Respiratory Syncytial Virus market in the coming years.  

• In October 2024, GSK has released encouraging results from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine designed to prevent lower respiratory tract disease (LRTD) over three RSV seasons. The trial included about 25,000 participants across 17 countries and focused on adults aged 60 and older, particularly those at higher risk. The primary objective of the trial was to evaluate the vaccine’s efficacy against RSV-LRTD following one RSV season.

• In July 2024, MSD (Merck & Co) announced encouraging topline results from its Phase IIb/III MK-1654-004 clinical trial evaluating clesrovimab as a preventive treatment for respiratory syncytial virus (RSV) in infants. This double-blind, randomized, placebo-controlled study aimed to examine the safety and efficacy of clesrovimab. Participants, which included healthy preterm and full-term infants, were randomly assigned to receive either a single dose of clesrovimab or a placebo.

• In May 2023, Arexvy is an innovative adjuvanted vaccine designed to combat respiratory syncytial virus (RSV), a significant cause of lower respiratory tract disease (LRTD) in individuals aged 60 and older. Developed by GlaxoSmithKline (GSK), a UK-based pharmaceutical company, Arexvy contains RSVPreF3, a genetically engineered protein derived from the virus, coupled with AS01E, GSK’s exclusive adjuvant.

• In May 2023, In order to treat respiratory syncytial virus (RSV) infection, Ascletis Pharma Inc. revealed that the China National Medical Products Administration (“NMPA”) has authorised a Phase IIa clinical trial for ASC10

Respiratory Syncytial Virus Overview

Respiratory Syncytial Virus (RSV) is a common respiratory virus that primarily affects the lungs and respiratory tract, often causing mild, cold-like symptoms. While it usually resolves on its own in healthy adults, RSV can be severe in infants, young children, and older adults, potentially leading to bronchiolitis and pneumonia. RSV spreads easily through droplets when an infected person coughs or sneezes, as well as through direct contact with surfaces. Symptoms include a runny nose, coughing, fever, and wheezing. In high-risk cases, treatment may involve supportive care, and prevention strategies include hand hygiene and, for vulnerable populations, protective vaccines.

Get a Free Sample PDF Report to know more about Respiratory Syncytial Virus Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight

Emerging Respiratory Syncytial Virus Drugs Under Different Phases of Clinical Development Include:

• Nirsevimab (MEDI-8897): MedImmune

• Sisunatovir: ReViral

• MVA-BN-RSV Vaccine: Bavarian Nordic

• RSVpreF (PF-06928316): Pfizer

• VAC 18193 (Ad26.RSV.preF): Janssen

• mRNA-1345: ModernaTX, Inc

• GSK3844766A: GlaxoSmithKline

• RSVPreF3: GlaxoSmithKline

• STR-V003/Placebo: Starna Therapeutics

• TNM001: Zhuhai Trinomab Pharma

• Sisunatovir: Pfizer

• RSVt Vaccine: Sanofi

• Deuremidevir Hydrobromide for Suspension: Vigonvita Life Sciences

• Nirsevimab: AstraZeneca

• TNM001: Zhuhai Trinomab Pharma

• Clesrovimab: Merck Sharp & Dohme LLC

• EDP-938: Enanta Pharmaceuticals

Route of Administration

Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Respiratory Syncytial Virus Pipeline Therapeutics Assessment

• Respiratory Syncytial Virus Assessment by Product Type

• Respiratory Syncytial Virus By Stage and Product Type

• Respiratory Syncytial Virus Assessment by Route of Administration

• Respiratory Syncytial Virus By Stage and Route of Administration

• Respiratory Syncytial Virus Assessment by Molecule Type

• Respiratory Syncytial Virus by Stage and Molecule Type

DelveInsight’s Respiratory Syncytial Virus Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Respiratory Syncytial Virus product details are provided in the report. Download the Respiratory Syncytial Virus pipeline report to learn more about the emerging Respiratory Syncytial Virus therapies

Respiratory Syncytial Virus Pipeline Analysis:

The Respiratory Syncytial Virus pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.

• Respiratory Syncytial Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Respiratory Syncytial Virus drugs and therapies

Respiratory Syncytial Virus Pipeline Market Drivers

• Rising government funding for treatment and proactive government initiatives generates profitable opportunities, the growing disease rate, advent of Targeted Therapies are some of the important factors that are fueling the Respiratory Syncytial Virus Market.

Respiratory Syncytial Virus Pipeline Market Barriers

• However, lack of adequate diagnostic facilities for RSV, limited awareness among parents and other factors are creating obstacles in the Respiratory Syncytial Virus Market growth.

Scope of Respiratory Syncytial Virus Pipeline Drug Insight    

• Coverage: Global

• Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others

• Key Respiratory Syncytial Virus Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others

• Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies

• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers 

Request for Sample PDF Report for Respiratory Syncytial Virus Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/